Become A Featured Company

Medical Cannabis Tech and Data Company Going Public Soon

Robin Lefferts

April 28th, 2021

App, Exclusive, News, Top Story

If cannabis is to be accepted by the medical community (meaning patients, doctors, researchers, pharma companies, regulators…), there is much to be done in terms of testing the plant, standardizing dosages, and cataloging its effects. After decades of prohibition, scientists are racing to determine and document the potential benefits of cannabis in the treatment of a wide range of conditions, including but not limited to seizures, PTSD, chronic pain, inflammatory disorders, and sleep problems. It’s a sprawling, wild industry with many inherent barriers to standardization, classification, and quantification.

One company, RYAH MedTech, has developed a suite of smart devices backed by powerful data analytics tools, designed to help researchers, clinical trial organizations, doctors, patients, growers, and dispensaries get the data they need to maximize their effectiveness. Data is the fundamental pillar of science and technology, and RYAH is able to capture seed-to-consumption information of different plant-based medicinal formulations through its Internet of Things (IoT) product ecosystem. As a result, RYAH can understand the roles of formulations and dosing in treatment, using quantitative data and qualitative feedback.

RYAH just announced the closing of its reverse takeover transaction, followed quickly by the announcement that the newly-combined public company will be trading on the Canadian Securities Exchange under the symbol ‘RYAH’ as of May 4th. Let’s take a look at what the company offers.

Click here to receive an investor presentation and public listing announcement

RYAH’s Products – Smart and Connected

RYAH’s business model is based on a few assumptions. First, controllable and trackable dosing of medical cannabis is desirable for everyone involved, from patients to doctors to researchers. Second, devices that offer such dosing should be comfortable and easy to use while providing data that can help people fine tune their products and medicines. Third, the path to scientific and medical acceptance lies in the gathering and understanding of massive amounts of disparate data on the medical use of cannabis.

 

On this basis, RYAH has developed a full suite of smart and interconnected delivery systems, along with the AI engine needed to sort through and make sense of the results of using these devices. The company offers a Smart Patch, a Smart Inhaler, and a Smart Pen for a variety of delivery systems. For the patient, each device is connected with a companion app to help perfect dosing and track the user experience. For the doctor, the company provides the RYAH MD platform, allowing them to remotely monitor and control the patient’s regimen through the connected devices. All of the data generated ties into the RYAH Cloud, the AI-powered data engine at the heart of the company’s business.

Information processed and analyzed through the Cloud helps all parties involved make intelligent decisions based on data. Doctors, clinics, and consumers can fine-tune their dosing regimens and product selections based on the analysis and suggestions of the Cloud. Growers can tweak their genetics and strain selection based on feedback from end-users filtered through the cloud. Clinical researchers can monitor in real-time the subjects’ experience and adjust accordingly. Without a comprehensive information system like this, everyone is kind of operating independently and somewhat in the dark. The RYAH Cloud and its interconnected devices can form the backbone of a smarter and more scientific body of medical cannabis (and other plant-based therapeutic) knowledge.

Where RYAH Has Been, and Where It Is Going

RYAH has been developing all of this over the past several years. The company touts the first cannabis patent in the AI industry and has a number of other device-related patents pending. RYAH is also a partner of one of the world’s largest medical cannabis clinical trials that covers five years and up to 50,000 patients, investigating treatments for chronic pain. RYAH’s database consists of input from over 300,000 medical cannabis patients, making it one of the world’s largest repositories of such information.

RYAH is actively expanding its business in several key areas. Building upon its previous clinical trial experience, the company creates custom solutions that cover everything from patient enrollment to data processing. Its solutions are HIPAAA compliant, completely controlled, and provide real-time access to patient data.

RYAH is also expanding its partnerships with organizations in every stage of the medical cannabis ecosystem, from producers to clinics to doctors to other research organizations. The more data, the better in this case.

With its stock slated to begin trading on Tuesday, May 4th, RYAH is ready to step out into the public view. Access to expanded capital markets could help to significantly fuel the company’s growth plans, and the timing couldn’t be more appropriate. The field of cannabis science and medicine is exploding right now, driven by a wave of legalization signaling an ever-increasing cultural acceptance of the plant. There is a lot of information to be harnessed, analyzed, and put to intelligent use. RYAH may have a solution that can rein it all in and get everyone rowing in the same direction. Stay tuned for further developments.

Click here to receive an investor presentation and public listing announcement

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading